Vanda Pharmaceuticals stock opened at $4.69 on Wednesday. Vanda Pharmaceuticals has a 1-year low of $3.61 and a 1-year high of $6.75. The firm has a market capitalization of $273.47 million, a PE ...
Shares of NASDAQ VNDA opened at $4.41 on Monday. The stock has a market capitalization of $257.15 million, a PE ratio of -15.75 and a beta of 0.77. Vanda Pharmaceuticals has a 12-month low of $3. ...
Vanda Pharmaceuticals and AnaptysBio announced an exclusive, global license agreement for the development and commercialization of imsidolimab.
Vanda Pharmaceuticals Inc. (Vanda) (Nasdaq: VNDA) and AnaptysBio, Inc. (Anaptys) (Nasdaq: ANAB) today announced an exclusive, ...
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
Analysts provide deeper insights through their assessments of 12-month price targets, revealing an average target of $18.0, a high estimate of $18.00, and a low estimate of $18.00. No alteration is ...
Vanda Pharmaceuticals (VNDA) and AnaptysBio (ANAB) announced an exclusive, global license agreement for the development and commercialization ...
D.C.’s Vanda Pharmaceuticals Inc. has locked in a deal with a West Coast biotech to commercialize a drug for a rare skin ...
A D.C. drugmaker is fighting the FDA on multiple fronts, from trying protect its intellectual property from generic competition to battles over getting more drugs to market.
Vanda Pharmaceuticals Inc. (NASDAQ: VNDA) and AnaptysBio, Inc. (Anaptys) (NASDAQ: ANAB) today announced an exclusive, global license agreement for the development and commercialization of imsidolimab ...
We sell different types of products and services to both investment professionals and individual investors. These products and services are usually sold through license agreements or subscriptions ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results